The completion of the Human Genome Project has suggested that there are about 30,000 genes. However, genomics has not led to the development of personalized medicine due to the gap between gene expression and transcription (proteomics), enzymatic activity (metabolic flux), and co- or post-translational modifications (phosphorylation, glycosylation). Our group develops analytical mass spectrometry techniques to study and quantify these biological markers. We are now embarking on the greatest challenge of all, synthesizing data between these OMES to understand the biological basis of disease, discover new diagnostic and prognostic markers, and develop new clinical tests. We seek to define inter- and intra-variability and use advanced statistical techniques to integrate data to answer biological questions.
David C. Muddiman is the Jacob and Betty Belin Distinguished Professor of Chemistry and Founder and Director of the W.M. Keck FTMS Laboratory for Human Health Research at North Carolina State University in Raleigh, NC. Prior to moving his research group to North Carolina State University, David was a Professor of Biochemistry and Molecular Biology and Founder and Director of the Mayo Proteomics Research Center at the Mayo Clinic College of Medicine in Rochester, MN. Prior to his appointment at the Mayo Clinic, David was an Associate Professor of Chemistry at Virginia Commonwealth University where he began his academic career as an assistant professor in 1997 with an adjunct appointment in the Department of Biochemistry and Molecular Biophysics where he was also a member of the Massey Cancer Center. David was born in Long Beach, CA in 1967 but spent most of his formative years in a small town in Pennsylvania. David received his B.S. in chemistry from Gannon University (Erie, PA) in 1990 and his Ph.D. in Analytical Chemistry from the University of Pittsburgh in 1995 under the auspices of David M. Hercules. He then was a Department of Energy Postdoctoral Fellow at Pacific Northwest National Laboratory in the Environmental Molecular Sciences Laboratory working with Richard D. Smith from 1995-1997.
Dr. Muddiman is Editor of Analytical and Biological Chemistry and Associate Editor of the Encyclopedia of Analytical Chemistry as well as on the Editorial Advisory Board of Mass Spectrometry Reviews, Molecular and Cellular Proteomics, Rapid Communications in Mass Spectrometry, and the Journal of Chromatography B. He also serves on the advisory board of the NIH Funded Complex Carbohydrate Research Center, University of Georgia and the Yale/NIDA Neuroproteomics Center, Yale University. Dr. Muddiman is currently a member of the ASMS Board of Directors and is the Treasurer and member of Executive Board of US-HUPO and recently was elected as President of US HUPO. His group has presented over 500 invited lectures and presentations at national and international meetings including 20 plenary/keynote lectures. His group has published over 200 peer-reviewed papers and has received four US patents. He is the recipient of the 2015 ACS Award in Chemical Instrumentation, 2010 Biemann Medal, American Society for Mass Spectrometry, 2009 NCSU Alumni Outstanding Research Award, the 2004 ACS Arthur F. Findeis Award, the 1999 American Society for Mass Spectrometry Research Award, and the 1990-91 Safford Award, University of Pittsburgh, for Excellence in Teaching. Dr. Muddiman's research directed at the development of innovative technologies, systems biology, and model organisms is funded by the National Institutes of Health, the National Science Foundation, the Department of Energy, and The United States Department of Agriculture.
The ultimate goals of our work are to quantitatively define biology and understand the role of individuality across a wide range of diseases. Our program requires a significant level of interaction with clinicians, basic scientists including biologists and chemists, statisticians as well as maintaining a large interdisciplinary group of scientists within our group driving innovations including advanced separations, state-of-the-art mass spectrometry, and bioinformatics. Collectively, the collaborative environment at North Carolina State University in concert with strategic collaborations with the Mayo Clinic College of Medicine, GSK, the UNC Chapel Hill Eshelman School of Pharmacy, puts our program on the cutting edge of basic and applied proteomics, glycomics and mass spectrometry imaging research.